6,280 Shares in Five Prime Therapeutics Inc (FPRX) Acquired by Quantamental Technologies LLC

Quantamental Technologies LLC acquired a new position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,280 shares of the biotechnology company’s stock, valued at approximately $58,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Five Prime Therapeutics during the fourth quarter worth $113,000. Vanguard Group Inc increased its position in shares of Five Prime Therapeutics by 3.0% during the third quarter. Vanguard Group Inc now owns 2,251,778 shares of the biotechnology company’s stock worth $31,344,000 after buying an additional 66,485 shares during the period. Vanguard Group Inc. increased its position in shares of Five Prime Therapeutics by 3.0% during the third quarter. Vanguard Group Inc. now owns 2,251,778 shares of the biotechnology company’s stock worth $31,344,000 after buying an additional 66,485 shares during the period. MetLife Investment Advisors LLC increased its position in shares of Five Prime Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 30,852 shares of the biotechnology company’s stock worth $429,000 after buying an additional 10,895 shares during the period. Finally, Platinum Investment Management Ltd. grew its holdings in Five Prime Therapeutics by 29.1% in the third quarter. Platinum Investment Management Ltd. now owns 121,576 shares of the biotechnology company’s stock worth $1,692,000 after purchasing an additional 27,376 shares during the period. Institutional investors own 86.09% of the company’s stock.

FPRX opened at $11.38 on Monday. Five Prime Therapeutics Inc has a fifty-two week low of $7.84 and a fifty-two week high of $22.75. The stock has a market cap of $403.60 million, a P/E ratio of -2.12 and a beta of 3.08.

A number of equities research analysts have commented on the stock. BidaskClub upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 27th. Zacks Investment Research raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, January 21st. ValuEngine raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 26th. Finally, Wedbush raised shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Thursday, January 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.33.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2019/02/11/6280-shares-in-five-prime-therapeutics-inc-fprx-acquired-by-quantamental-technologies-llc.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Story: Earnings Per Share

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply